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Introduction
Mycobacterium tuberculosis (Mtb) is estimated to have infected one third of the world’s 
population and continues to be a significant cause of mortality and morbidity [1]. There is a 
need for new and improved diagnostics or treatment monitoring tools and blood based 
mRNA diagnostics are a potential solution [2]. Gene expression microarray analysis of 
human blood has been widely used to profile the host transcriptional response in active 
tuberculosis (TB) with the aim of identifying potential biomarkers as well as to better 
understand the host immune response [2]. So far, there has been a relative lack of 
concordance in the actual genes being identified from the published studies [2–4], although 
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there has been agreement in some of the pathways identified. Interferon signalling has been 
identified as a dominant signature in many of the individual studies [2], however when 
significant gene lists were combined from eight publicly available TB data-sets TREM1 
signalling became the most significant pathway [5].
We therefore undertook this study to collectively reanalyse the publicly available datasets 
using differing methodologies to identify robustly differentially expressed genes which 
could distinguish active TB from controls. These identified genes are potential candidates 
for blood based mRNA biomarkers of active disease and additionally could provide valuable 
information regarding the immune and inflammatory response underlying TB pathogenesis.
Methods
In August 2014 a comprehensive search of Pubmed as well as microarray depositories was 
undertaken. Publicly available datasets that had active TB patients and healthy controls, 
latently infected or patients post treatment were identified and retained. The latter three 
cohorts are synonymous transcriptionally at the group level [3, 6–8]. HIV infected 
individuals were excluded from this analysis.
Where possible, data were imported in its raw format, Illumina and Agilent data were 75th 
centile normalised, and Affymetrix data RMA quantile normalised. If raw data were not 
available then the authors’ normalisation was used. All datasets were then filtered for low 
expression transcripts (transcripts with expression 2 fold change (FC) from the median in at 
least 10% of all samples retained) followed by statistical filtering (independent t-test with 
Benjamini Hochberg multiple testing correction q-value <0.05). Probe/transcript IDs were 
matched to Entrez gene identifiers for each dataset. Multiple represented genes were filtered 
and the most significant (by q-value) retained. Venn Mapping [9] was used to check 
significance of the overlaps between any two datasets. Meta-profiling [10] of the significant 
gene lists was then undertaken to identify the number of overlaps required for inclusion in 
the meta-signature, additionally only those genes which were expressed in a consistent 
direction of regulation for at least the number of determined overlaps were retained as the 
meta-signature.
Modular analysis [11] was undertaken of compatible datasets, it was not possible to analyse 
GSE56153, GSE34608 and GSE28623 with this method as their technology platforms were 
not supported by the tool.
The canonical pathway, gene network analysis, gene function annotation and upstream 
analyses were generated through the use of IPA (Ingenuity® Systems, www.ingenuity.com).
Results
Modular and meta-profiling identify a common transcriptional response of patients with TB 
versus healthy controls, patients post-treatment and asymptomatic latently infected 
individuals
Sixteen datasets were identified for inclusion in the meta-analysis (GSE39939, GSE39940, 
GSE54992, GSE37250, GSE31348, GSE36238, GSE42825, GSE42826, GSE42830, 
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GSE40553, GSE56153, GSE34608, GSE28623, GSE19444, GSE19442 and GSE19439). 
Modular analysis of these datasets revealed similarities in the modular profiles with over-
expression of modules annotated as cytotoxic, interferon, inflammation and DC/apoptosis, 
and under-expression of modules annotated as B-cells, T-cells, lymphocyte activation and 
mitochondrial stress (Figure 1A). Two datasets (GSE54992 and GSE36238) had different 
weaker modular patterns with less modules identified as significantly different from the 
control group; these two were also the smallest in terms of total number of individuals 
within the datasets.
Independently for each dataset differentially expressed genes between controls and TB 
groups were identified. There was significant overlap between the differentially expressed 
gene lists across the datasets with no difference in degree of overlap dependent on the choice 
of control group (Figure 1B). Meta-profiling identified 380 genes which were identified in 
nine or more datasets in a consistent direction of regulation (Figure 1C). Upregulated genes 
were more consistently identified across datasets than down-regulated genes (Figure 1D). 
Five genes were identified in all 16 datasets AIM2, BATF2, FCGR1B, HP and TLR5.
IFN-γ was the top predicted upstream regulator of these 380 meta-signature genes with 54 
genes directly or indirectly linked to IFN-γ within the IPA database (Data not shown). The 
380 meta-signature had enrichment for IPA canonical pathways involved in pattern 
recognition, interferon signalling, IL-6 signalling, TREM-1 signalling and complement 
(Data not shown). Based on these findings a curated cartoon summarising the major 
functional groups of genes and their relationships was created (Figure 1E).
Discussion
In this study we have identified a 380 gene meta-signature of active TB compared to healthy 
controls, patients post-treatment and asymptomatic latently infected individuals which 
showed enrichment for both innate and adaptive immune functions.
Two main methodologies were used to analyse the publicly available data: modular analysis 
and meta-profiling. Modular analysis depends on identifying differences in coordinately 
expressed groups of genes (modules) rather than individual genes [11]. We identified 
remarkable similarity between the datasets with over-expression of modules annotated with 
interferon, inflammation functions, monocyte and neutrophil functions, and under-
expression of B and T-cell modules. These findings are in keeping with the individual 
studies which have included grouped modular analysis [7, 8]. Where grouped modular 
profiles were less consistent this may have resulted from the small cohort sizes used and 
emphasises the need for individual studies to be appropriately powered to detect all 
differentially expressed genes.
Using meta-profiling we found that 380 genes were consistently differentially expressed in 
nine or more datasets, with 5 genes identified as differentially expressed in all 16 datasets. 
These 5 genes included AIM2, BATF2, FCGR1B and HP which have been shown to 
potentially play a role following Mtb infection [12–15]. A role for TLR5 has yet to be 
described and identification of such differentially regulated genes may therefore be part of a 
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programmatic response rather than specifically targeted for a tailored response to the 
pathogen.
Analysis of the 380 genes comprising the meta-signature identified IFN-γ as the most 
significant potential upstream regulated molecule, with a large network of IFN-γ regulated 
genes present within the 380 genes. IFN-γ is critical for control of mycobacterial disease in 
humans, with mutations either in the IFN-γ receptor or STAT1 resulting in increased 
susceptibility [16]. However, upregulation of gene expression molecules downstream of 
Type I IFN signalling was also observed, of relevance to TB exacerbation, since Type I IFN 
has been shown to antagonise signalling downstream of IFN-γ [17]. Thus, capturing the 
overall picture of significant enrichment may be more informative than identification of one 
individual pathway, as shown in the summary cartoon (Figure 1E). A number of immune 
pathways/functions are enriched for within the meta-signature including multiple pattern 
recognition receptors, cytokines, the inflammasome, complement and immunoglobulin. This 
supports diverse findings obtained from both mouse and human studies that the immune 
response following Mtb infection is complex and can be cross-regulatory [16].
This study confirms the reproducibility of blood based transcriptional analysis to identify the 
innate and adaptive host response in TB. It also identifies that upregulated mRNA transcripts 
are more reliably identified and highlights several mRNA candidates which could 
collectively be used as potential biomarkers of active disease. These findings have 
implications for the design and implementation of mRNA expression tools to support 
diagnostics and treatment monitoring of TB.
Funding
SB and AOG were supported by the Medical Research Council, United Kingdom (U117565642), now The Francis 
Crick (AOG Crick Budget 10126). SB was jointly funded by the UK Medical Research Council (MRC) and the UK 
Department for International Development (DFID) under the MRC/DFID Concordat agreement. (MR/J010723/1). 
GS was supported in part by the Department of Health via the National Institutes of Health Research 
comprehensive Biomedical Research Centre award to Guy’s and St Thomas’ National Health Service Foundation 
Trust in partnership with King’s College London. This study received financial support from SILA. The funders had 
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
1. World Health Organization. World Health Organisation: Global tuberculosis report 2014. 2014. 
2. Blankley S, Berry MP, Graham CM, Bloom CI, Lipman M, O'Garra A. The application of 
transcriptional blood signatures to enhance our understanding of the host response to infection: the 
example of tuberculosis. Philosophical transactions of the Royal Society of London Series B, 
Biological sciences. 2014; 369 20130427. 
3. Bloom CI, Graham CM, Berry MP, et al. Transcriptional blood signatures distinguish pulmonary 
tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PloS one. 2013; 8:e70630. 
[PubMed: 23940611] 
4. Kaforou M, Wright VJ, Oni T, et al. Detection of Tuberculosis in HIV-Infected and -Uninfected 
African Adults Using Whole Blood RNA Expression Signatures: A Case-Control Study. PLoS 
medicine. 2013; 10:e1001538. [PubMed: 24167453] 
5. Joosten SA, Fletcher HA, Ottenhoff TH. A helicopter perspective on TB biomarkers: pathway and 
process based analysis of gene expression data provides new insight into TB pathogenesis. PloS 
one. 2013; 8:e73230. [PubMed: 24066041] 
Blankley et al. Page 4
Eur Respir J. Author manuscript; available in PMC 2016 December 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
6. Bloom CI, Graham CM, Berry MP, et al. Detectable changes in the blood transcriptome are present 
after two weeks of antituberculosis therapy. PloS one. 2012; 7:e46191. [PubMed: 23056259] 
7. Cliff JM, Lee JS, Constantinou N, et al. Distinct phases of blood gene expression pattern through 
tuberculosis treatment reflect modulation of the humoral immune response. The Journal of 
infectious diseases. 2013; 207:18–29. [PubMed: 22872737] 
8. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood 
transcriptional signature in human tuberculosis. Nature. 2010; 466:973–7. [PubMed: 20725040] 
9. Smid M, Dorssers LC, Jenster G. Venn Mapping: clustering of heterologous microarray data based 
on the number of co-occurring differentially expressed genes. Bioinformatics. 2003; 19:2065–71. 
[PubMed: 14594711] 
10. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies 
common transcriptional profiles of neoplastic transformation and progression. Proceedings of the 
National Academy of Sciences of the United States of America. 2004; 101:9309–14. [PubMed: 
15184677] 
11. Chaussabel D, Quinn C, Shen J, et al. A modular analysis framework for blood genomics studies: 
application to systemic lupus erythematosus. Immunity. 2008; 29:150–64. [PubMed: 18631455] 
12. Saiga H, Kitada S, Shimada Y, et al. Critical role of AIM2 in Mycobacterium tuberculosis 
infection. International immunology. 2012; 24:637–44. [PubMed: 22695634] 
13. Tussiwand R, Lee WL, Murphy TL, et al. Compensatory dendritic cell development mediated by 
BATF-IRF interactions. Nature. 2012; 490:502–7. [PubMed: 22992524] 
14. Jacobsen M, Repsilber D, Gutschmidt A, et al. Candidate biomarkers for discrimination between 
infection and disease caused by Mycobacterium tuberculosis. Journal of molecular medicine. 
2007; 85:613–21. [PubMed: 17318616] 
15. Kasvosve I, Gomo ZA, Mvundura E, et al. Haptoglobin polymorphism and mortality in patients 
with tuberculosis. The international journal of tuberculosis and lung disease : the official journal of 
the International Union against Tuberculosis and Lung Disease. 2000; 4:771–5.
16. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPR. The immune response 
in tuberculosis. Annual review of immunology. 2013; 31:475–527.
17. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. 
Nature reviews Immunology. 2015; 15:87–103.
Blankley et al. Page 5
Eur Respir J. Author manuscript; available in PMC 2016 December 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1: Modular and meta-profiling identifying common transcriptional response.
(A) Modular analysis of 13 publically available and compatible datasets of TB compared to 
control groups. 38 annotated modules are displayed as a heatmap with red indicating 
significant over-abundance of transcripts and a blue indicating significant under-abundance 
(p <0.05). The colour intensity represents the percentage of genes in that module which are 
significantly differentially expressed. Two datasets with different modular profiles marked 
with asterisks. (B) Venn Mapper used to identify significance of overlap between any two 
differentially expressed gene lists. Significance of overlap between significant gene lists 
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calculated by Venn Mapper programme, with methodology adapted from Smid et al [9]. 
Significant genes identified following filtering of probes for low expression (probes 
eliminated if expression less than 2FC from median normalised value in 10% or more of 
samples), followed by statistical filtering; independent t-test with Benjamini Hochberg 
multiple testing correction between TB and control group. Probes were then matched to 
Entrez gene IDs which was used as the reference “array” for analysis. The fold change 
representation for each gene was the mean fold change of TB group compared to control 
group, where genes were multiply represented on an array the fold change associated with 
the most significant q-value was chosen. (C) Differentially expressed genes (DEGs) were 
identified for each of the sixteen datasets (probes filtered for low expression, followed by 
statistical filtering; independent t-test with Benjamini Hochberg multiple testing correction 
between TB and control group) and then using meta-profiling to simulate the data and 
identify the number of overlaps to define the meta-signature (shaded grey). (D) Genes were 
grouped by number of datasets in which they were significantly identified, and the 
percentage calculated which were upregulated (direction of regulation relative to control 
group; where there were inconsistencies in direction of regulation across datasets the 
direction most often observed was used to determine direction). (E) Curated cartoon of 380 
meta-signature generated using IPA and IPA knowledge base.
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